Blaze Medical Devices, LLC

Functional Fluidics Inc.

Michael Tarasev

Kenneth Alfano

Gene Parunak

Aaron Kehrer

Terrance Boyd

Steven Meines

Xiufeng Gao

Marta Ferranti

Sumita Chakraborty

Lucas Gelmini

A method for assessing an effect, such as a treatment, disease, or passage of time on a cellular unit of an organism includes providing a sample including a cellular unit subject to the effect in a supporting medium in a hermetically sealed container. The container is deoxygenated to induce at least one of a predetermined amount of hypoxia and a predetermined rate of oxygen consumption in the medium. Values for variables associated with the medium and/or the cellular unit are determined at each of a plurality of different times. Various combinations of the predetermined amount of hypoxia, the predetermined rate of oxygen consumption, the values for the variables associated with the medium and/or cellular unit, and the times and then correlated to generate a multi-dimensional surface. This surface is compared with another surface correlating corresponding values relating to another cellular unit such as one not subject to the effect.

System and method for assessing an effect on cellular units in an organism

A method for assessing an effect of hypoxia on a tissue includes providing a sample of the tissue in a hermetically sealed container, determining a first amount of a reaction substrate (e.g., protocatechuic acid) to be introduced into the sealed container and determining a second amount of a reaction enzyme (e.g., protocatechuate dioxygenase) to be introduced into the sealed container. The method further includes introducing the reaction substrate and the reaction enzyme into the sealed container. At least one of the first amount of the reaction substrate and the second amount of the reaction enzyme is selected to induce at least one of a predetermined amount of hypoxia less than anoxia and a predetermined rate of hypoxia in the tissue during a reaction between the reaction substrate and the reaction enzyme. Values of properties of the tissue can be measured before and after the reaction to assess effects of hypoxia.

Method for assessing the effects of hypoxia on tissues

A bead mill and an associated bead-mill-based machine for testing mechanical fragility of red blood cells, employing a cartridge configured to contain a sample while cells get stressed via bead oscillation and, in the case of the fragility testing machine, also while lysis levels get detected, for presentation of fragility information.

Method of using bead milling in erythrocyte fragility testing

A method using variable bead-oscillation-based stress parameters, including relative bead dimensionality or other structural features as well as stress duration or intensity or overall magnitude, in inducing different shear stresses in biological samples, for testing the effects of different combinations of various defined stress conditions.

Method and system for inducing controlled and varied fluid stresses by bead oscillation

Bead mill and method of use

The present disclosure describes an apparatus for quantifying the quality degradation of individual stored red blood cell (RBC) units, thereby yielding information to improve decisions regarding their respective allocation, patient suitability, and use. The apparatus for quantifying the quality degradation of individual stored (RBC) units comprises: a hemolysis unit; an optical analysis unit; and a computation unit. This apparatus is amenable to clinical implementation as well as indicative of any given unit's relative viability and thus prospective efficacy. This would provide clinicians with actual data on RBC quality when making decisions about which and how many units to use for transfusion of a given patient. Moreover, deploying this testing throughout the supply chain will improve distribution, planning, and inventory control decisions. A vital aspect of this testing system is the accumulation of copious output and other associated data and the mathematical analyses thereof to optimize algorithms by which to characterize each subsequent test output as meaningfully as possible. While the present invention is directed toward applications in blood quality control, the core technology of 'quantifying RBC fragility via stress-induced hemolysis and subsequent optical and computational analysis' could have broader application, such as in disease diagnosis.

Apparatus to characterize blood and red blood cells via erythrocyte membrane fragility quantification

A method for quantifying the quality degradation of individual stored red blood cell (RBC) units, thereby yielding information to improve decisions regarding their respective allocation, patient suitability, and use. The method comprises: a hemolysis step; an optical analysis step; and a computation step. The method is amenable to clinical implementation as well as indicative of any given unit's relative viability and thus prospective efficacy. This would provide clinicians with actual data on RBC quality when making decisions about which and how many units to use for transfusion of a given patient. Moreover, deploying this testing throughout the supply chain will improve distribution, planning, and inventory control decisions. A vital aspect of this testing method is the accumulation of copious output and other associated data and the mathematical analyses thereof to optimize algorithms by which to characterize each subsequent test output as meaningfully as possible. While the present invention is directed toward applications in blood quality control, the core technology of 'quantifying RBC fragility via stress-induced hemolysis and subsequent optical and computational analysis' could have broader application, such as in disease diagnosis.

Method to characterize blood and red blood cells via erythrocyte membrane fragility quantification

The present disclosure describes an apparatus and associated method for quantifying the quality degradation of individual stored red blood cell (RBC) units, thereby yielding information to improve decisions regarding their respective allocation, patient suitability, and use. This apparatus and the methods of its use are amenable to clinical implementation as well as indicative of any given unit's relative viability and thus prospective efficacy. This would provide clinicians with actual data on RBC quality when making decisions about which and how many units to use for transfusion of a given patient. Moreover, deploying this testing throughout the supply chain will improve distribution, planning, and inventory control decisions. A vital aspect of this testing system is the accumulation of copious output and other associated data and the mathematical analyses thereof to optimize algorithms by which to characterize each subsequent test output as meaningfully as possible. While the present invention is directed toward applications in blood quality control, the core technology of 'quantifying RBC fragility via stress-induced hemolysis and subsequent optical and computational analysis' could have broader application, such as in disease diagnosis. The apparatus for quantifying the quality degradation of individual stored (RBC) units comprises: a hemolysis unit; an optical analysis unit; and a computation unit. Similarly, the associated process for quantifying the quality degradation of individual stored (RBC) units comprises: a hemolysis step; an optical analysis step; and a computation step.

Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification

Systems and methods for determining the concentration of hemoglobin derivatives in bodily fluids include devices for measuring and comparing the absorption of electromagnetic radiation by cellular and cell-free hemoglobin at two or more wavelengths in the Soret region. Systems and methods for determining erythrocyte membrane fragility include devices for measuring the concentration of at least one cell-free hemoglobin derivative, and using the absorption properties of cellular and cell-free hemoglobin derivatives in the Soret region.

Growing community of inventors

Pinckney, MI, United States of America

Michael Tarasev